News | January 19, 2010

New Study Shows Lp(a) Joins LDL as Heart Disease Risk Factor

January 20, 2010 – LDL is not the only "bad cholesterol" according to a new study. A lipoprotein in the bloodstream called Lp(a) can also be labeled "bad cholesterol," according to the study Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease, recently published in the New England Journal Of Medicine.

"This study will lead to changes in how physicians approach cholesterol testing and treatment because it demonstrates a growing need for expanded lipid profiling," said Michael Cobble, M.D., a family doctor at Canyons Medical Center in Sandy, Utah, and chief medical officer of the blood testing equipment company Atherotech Inc. "This was a well-designed study built on a foundation of several other studies showing a strong association between Lp(a) and heart disease. It gives us conclusive evidence that there is a link between increasing levels of Lp(a) and increasing risk of coronary artery disease, and it indicates that we can identify this added risk."

Cobble said the findings also help to partially explain why the standard cholesterol test fails to detect up to half the people at risk for coronary disease, and why many people with "normal cholesterol levels" still end up having heart attacks.

Standard cholesterol tests check for levels of LDL, HDL, triglycerides and total cholesterol. Atherotech developed the VAP (Vertical Auto Profile) Cholesterol Test that includes Lp(a) as part of its standard panel. Cobble said that while LDL, non-HDL and apoB remain the most dangerous and reliable indicators of heart disease risk, Lp(a) is now a strong additive predictor of risk.

Comprehensive lipid testing provided by the VAP Cholesterol Test reports Lp(a) along with other important cholesterol subclasses, non-HDL, emerging heart disease risk factors such as the apoB/apoAI ratio, low-density lipoprotein remnants and small dense LDL as well as triglyceride-rich remnant lipoproteins. The test also does not require fasting and provides a direct measurement of LDL.

The only currently available drug for lowering Lp(a) is niacin, although other drugs are currently in development.

For more information: www.thevaptest.com


Related Content

News | Cardiovascular Clinical Studies

May 1, 2024 β€” A study in more than 3,000 US counties, with 315 million residents, has suggested that air pollution is ...

Home May 01, 2024
Home
News | Cardiovascular Clinical Studies

April 30, 2024 β€” Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart ...

Home April 30, 2024
Home
News | Cardiovascular Clinical Studies

April 24, 2024 β€”Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 β€” Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 β€” CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 β€” Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 β€” People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
Subscribe Now